+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 110 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 5440502
Description Jump to:
The global glioblastoma multiforme treatment market size is expected to reach USD 5.10 billion by 2030. It is expected to expand at a CAGR of 9.7% from 2023 to 2030. The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy.

In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years.

Moreover, companies are collaborating to develop novel treatments. For instance, in October 2019, Advaxis, Inc., a clinical-stage biotechnology company, announced a research collaboration agreement with the University of California for the development and commercialization of novel immunotherapy by using the company’s Lm Technology in mouse tumor models of glioblastoma multiforme. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme.

Existing companies are willing to acquire new companies with pipeline products to diversify their product portfolio. For instance, in May 2019, Merck announced the upfront USD 1.1 billion acquisition of Peloton Therapeutics, which grants it access to the PT2977 under trial glioblastoma drug. This acquisition is likely to strengthen its pipeline and improve its future revenue-generation ability.

Various initiatives undertaken by the governments and non-government bodies across the globe to increase awareness by educating people living with glioblastoma multiforme and raising funds for R&D activities and treatment are expected to fuel the glioblastoma multiforme (GBM) treatment market growth during the forecast period. For instance, Ping Mobile, a mobile messaging platform, has launched a mobile campaign to increase awareness about brain cancer. This helps in raising awareness about glioblastoma multiforme and motivating people to donate money for glioblastoma multiforme research activities.

Organizations such as the National Brain Tumor Society, Brain Tumour Foundation of Canada, and Cure Brain Cancer Foundation are also involved in many awareness campaigns to raise awareness among people about the condition. In the U.K., March is Brain Tumor Awareness month, a campaign established by member charities of Brain Tumor Research. The main aim of the campaign is to spread awareness about the lack of funding for brain tumor research, and it helps people understand brain tumors and their treatment. Moreover, Novocure undertook many activities to spread awareness about glioblastoma multiforme during Brain Tumor Awareness Month.

Glioblastoma Multiforme Treatment Market Report Highlights

  • Based on treatment, in 2020, radiation therapy dominated the market with a revenue share of 37.0% in 2022, owing to improved survival rates, as radiation therapy is most often recommended as the first line of treatment or in combination with chemotherapy and surgery
  • By drug class, the others segment accounted for the largest revenue share in 2022. The segment includes everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA)
  • The hospital segment held the largest revenue share in the glioblastoma multiforme treatment market in 2022 and is anticipated to maintain its leading position during the forecast period. Patients prefer hospitals in terms of treatment accessibility and convenience
  • Asia Pacific is expected to register the fastest growth rate of 11.1% over the forecast period, owing to various factors such as the entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in the healthcare sector
  • North America accounted for the largest share of 43.4% in 2022. Government support for the development of the healthcare sector, high awareness about rare disorders, easy accessibility to quality medical facilities, and favorable reimbursement policies are among the key factors responsible for the regional market growth


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Treatment
1.1.2. Drug class
1.1.3. End Use
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment outlook
2.2.2. Drug class outlook
2.2.3. End-use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.2. Market Restraint Analysis
3.5. Glioblastoma Multiforme Treatment Market Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Forces
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic Landscape
Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Estimates & Trend Analysis
4.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
4.2. Glioblastoma Multiforme Treatment Market: Treatment Movement & Market Share Analysis, 2022 & 2030
4.3. Surgery
4.3.1. Surgery market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Radiation Therapy
4.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Chemotherapy
4.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Targeted Therapy
4.6.1. Targeted Therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Tumor Treating Field (TTF) Therapy
4.7.1. Tumor treating field (TTF) therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Immunotherapy
4.8.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Glioblastoma Multiforme Treatment Market: Drug Class Estimates & Trend Analysis
5.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
5.2. Glioblastoma Multiforme Treatment Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
5.3. Temozolomide
5.3.1. Temozolomide market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Bevacizumab
5.4.1. Bevacizumab market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Lomustine
5.5.1. Lomustine market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Carmustine Wafers
5.6.1. Carmustine Wafers market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Glioblastoma Multiforme Treatment Market: End Use Estimates & Trend Analysis
6.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
6.2. Glioblastoma Multiforme Treatment Market: End-use Movement & Market Share Analysis, 2022 & 2030
6.3. Hospitals
6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Clinics
6.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Ambulatory Surgical Centers
6.5.1. Ambulatory Surgical Centers market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Glioblastoma Multiforme Treatment Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Glioblastoma Multiforme Treatment Market by Region: Key Takeaway
7.3. North America
7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.3.2. U.S.
7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.6. Sweden
7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.7. Norway
7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4.8. Denmark
7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7. MEA
7.7.1. Saudi Arabia
7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7.2. South Africa
7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
8.2.1. Merck & Co., Inc.
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Teva Pharmaceutical Industries Ltd.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Sun Pharmaceutical Industries Ltd.
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Hoffmann-La Roche Ltd.
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Pfizer, Inc.
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Amgen, Inc.
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Arbor Pharmaceuticals, LLC
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Amneal Pharmaceuticals
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Karyopharm Therapeutics, Inc.
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 3 North America glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 4 North America glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 5 North America glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 6 U.S. glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 7 U.S. glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 8 U.S. glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 9 Canada glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 10 Canada glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 11 Canada glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 12 Europe glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 13 Europe glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 14 Europe glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 15 Europe glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 16 Germany glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 17 Germany glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 18 Germany glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 19 UK glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 20 UK glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 21 UK glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 22 France glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 23 France glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 24 France glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 25 Italy glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 26 Italy glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 27 Italy glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 28 Spain glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 29 Spain glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 30 Spain glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 31 Sweden glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 32 Sweden glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 33 Sweden glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 34 Norway glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 35 Norway glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 36 Norway glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 37 Denmark glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 38 Denmark glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 39 Denmark glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 40 Asia Pacific glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 41 Asia Pacific glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 42 Asia Pacific glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 43 Asia Pacific glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 44 China glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 45 China glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 46 China glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 47 Japan glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 48 Japan glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 49 Japan glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 50 India glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 51 India glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 52 India glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 53 Thailand glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 54 Thailand glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 55 Thailand glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 56 South Korea glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 57 South Korea glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 58 South Korea glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 59 Australia glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 60 Australia glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 61 Australia glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 62 Latin America glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 63 Latin America glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 64 Latin America glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 65 Latin America glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 66 Brazil glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 67 Brazil glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 68 Brazil glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 69 Mexico glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 70 Mexico glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 71 Mexico glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 72 Argentina glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 73 Argentina glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 74 Argentina glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 79 South Africa glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 80 South Africa glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 81 South Africa glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 85 UAE glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 86 UAE glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 87 UAE glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 88 Kuwait glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 89 Kuwait glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 90 Kuwait glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Glioblastoma multiforme treatments: Market outlook
Fig. 9 Glioblastoma multiforme treatments: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Glioblastoma multiforme treatments market driver impact
Fig. 15 Glioblastoma multiforme treatments market restraint impact
Fig. 16 Glioblastoma multiforme treatments market strategic initiatives analysis
Fig. 17 Glioblastoma multiforme treatments market: Treatment movement analysis
Fig. 18 Glioblastoma multiforme treatments market: Treatment outlook and key takeaways
Fig. 19 Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Tumor treating field (TTF) therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Immunotherapy therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Glioblastoma multiforme treatments market: Drug class movement analysis
Fig. 26 Glioblastoma multiforme treatments market: Drug class outlook and key takeaways
Fig. 27 Temozolomide market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Bevacizumab market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Lomustine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Carmustine wafers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Glioblastoma multiforme treatments market: End-use movement analysis
Fig. 33 Glioblastoma multiforme treatments market: End-use outlook and key takeaways
Fig. 34 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Ambulatory Surgical Centers market estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 37 Global glioblastoma multiforme treatments market: Regional movement analysis
Fig. 38 Global glioblastoma multiforme treatments market: Regional outlook and key takeaways
Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Companies Mentioned

  • Merck & Co., Inc.
  • Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Amgen, Inc.
  • Arbor Pharmaceuticals, LLC
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages110
PublishedSeptember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 2.46 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.1 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Global Glioblastoma Multiforme Treatment Market by Type (Chemotherapy, Combined Modality Therapy, Medications), End-Users (Hospitals, Speciality Centers) - Forecast 2024-2030 - Product Image

Global Glioblastoma Multiforme Treatment Market by Type (Chemotherapy, Combined Modality Therapy, Medications), End-Users (Hospitals, Speciality Centers) - Forecast 2024-2030

  • Report
  • 187 Pages
  • Global
From
Glioblastoma Multiforme Treatment (GBM): Global Strategic Business Report - Product Image

Glioblastoma Multiforme Treatment (GBM): Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Recurrent Glioblastoma Multiforme Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Recurrent Glioblastoma Multiforme Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 95 Pages
  • Global
From
Global Glioblastoma Multiforme Treatment Market Report and Forecast 2024-2032 - Product Image

Global Glioblastoma Multiforme Treatment Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Glioblastoma Multiforme Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Glioblastoma Multiforme Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.